News | September 21, 2008

Edwards Lifesciences Presents New Transcatheter Heart Valve Data

September 22, 2008 - New data on the Edwards SAPIEN transcatheter heart valve with the Ascendra transapical delivery system was presented at the 22nd annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Lisbon, Portugal.

Interim follow-up results from the pre-commercial transapical PARTNER EU registry of 67 transapical patients were presented on Sept. 13 and showed a 30-day survival of 82 percent and a six-month survival of 56 percent. PARTNER EU is a European registry conducted primarily in 2007 that represents Edwards’ early transapical experience.

The 30-day results from the post-approval commercial SOURCE registry were also presented. SOURCE is designed to evaluate commercial use of the Edwards SAPIEN valve with a prescribed training and proctoring program. It is a registry of procedural and short-term clinical outcomes. The current data reflect 309 cases at hospitals in 12 European countries. Survival at 30 days was 88 percent.

The largest single site transapical experience from Leipzig was also updated, and showed continued progress in early and late mortality on a cohort of 113 patients. Six-month survival was 74 percent and 12-month survival was 71 percent.

In addition to the data presentations, a live case transmitted from Universität Leipzig on Saturday demonstrated the transcatheter valve replacement procedure with the Ascendra transapical delivery system. The patient received a thoracic epidural and was not intubated, which allowed the patient to be awake throughout the procedure. The Edwards SAPIEN transcatheter valve was successfully deployed.

Six-month transfemoral data from PARTNER EU and 30-day transfemoral data from SOURCE will be presented at TCT 2008 in October.

The Edwards SAPIEN transcatheter heart valve is approved for commercial sale in Europe. In the U.S. it is an investigational device that is not available for sale. The Edwards SAPIEN valve is being studied in the U.S. PARTNER trial, which is a randomized trial that only recently began enrolling transapical patients.

For more information: www.edwards.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init